Literature DB >> 6332826

In vitro antigen-induced antibody responses to hepatitis B surface antigen in man. Kinetic and cellular requirements.

T R Cupps, J L Gerin, R H Purcell, P K Goldsmith, A S Fauci.   

Abstract

In this report we define the parameters of the human immune response after immunization with hepatitis B vaccine. 2 wk after booster immunization, there is significant spontaneous secretion of antibody to hepatitis B surface antigen (anti-HBs IgG), which is not further augmented by stimulation with antigen or pokeweed mitogen (PWM). By 4 wk there is little spontaneous secretion of specific antibody, and low doses of antigen or PWM produce significant increases in the amount of anti-HBs IgG produced. By 8 wk the peripheral blood mononuclear cells are refractory to stimulation by antigen, but anti-HBs IgG is produced in response to PWM. 0.5 yr or more after the last immunization, some individuals will manifest an antigen-induced specific antibody response. This induction of anti-HBs IgG by hepatitis B surface antigen (HBsAg) is monocyte- and T cell-dependent. Note that there is a dichotomy in the T cell response to HBsAg. The specific antibody response is clearly T cell dependent, but no in vitro T cell proliferative response to HBsAG could be demonstrated in the immunized individuals. Although the precise reason for the absent proliferative response to HBsAg despite well-established humoral immunity has not been determined, there was no evidence to suggest nonspecific suppression by HBsAg or the presence of an adherent suppressor cell population. The ability to evaluate antigen-induced, antigen-specific responses to HBsAg will be useful in defining the unique interaction between the human immune response and this clinically important viral agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332826      PMCID: PMC425286          DOI: 10.1172/JCI111529

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

2.  Modulation of the host response in human schistosomiasis. I. Adherent suppressor cells that inhibit lymphocyte proliferative responses to parasite antigens.

Authors:  E A Ottesen
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

3.  Isolation of B and T lymphocytes by nylon fiber columns.

Authors:  C Werner; P T Klouda; M C Corréa; P Vassalli; M Jeannet
Journal:  Tissue Antigens       Date:  1977-04

4.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

5.  Viral inhibition of lymphocyte mitogenesis. I. Evidence for the nonspecificity of the effect.

Authors:  M A Wainberg; E Israel
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

6.  Radioimmunoassay for albumin-binding sites associated with HBsAg: correlation of results with the presence of e-antigen in serum.

Authors:  A R Neurath; N Strick
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

7.  A receptor for polymerized human and chimpanzee albumins on hepatitis B virus particles co-occurring with HBeAg.

Authors:  M Imai; Y Yanase; T Nojiri; Y Miyakawa; M Mayumi
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

8.  Specific in vitro antibody response to influenza virus by human blood lymphocytes.

Authors:  R E Callard
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

9.  Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans.

Authors:  R Dolin; B R Murphy; E A Caplan
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

10.  Antigen-specific suppressor cells and suppressor factors in human filariasis with Brugia malayi.

Authors:  W F Piessens; S Ratiwayanto; S Tuti; J H Palmieri; P W Piessens; I Koiman; D T Dennis
Journal:  N Engl J Med       Date:  1980-04-10       Impact factor: 91.245

View more
  11 in total

1.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans.

Authors:  E Egea; A Iglesias; M Salazar; C Morimoto; M S Kruskall; Z Awdeh; S F Schlossman; C A Alper; E J Yunis
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

2.  The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen.

Authors:  P J Wismans; J van Hattum; G C De Gast; H J Endeman; J Poel; B Stolk; T Maikoe; G C Mudde
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

3.  In vitro induction of HBsAg-specific CD8 CD11 human suppressor T cells.

Authors:  V Barnaba; G Ruberti; M Levrero; F Balsano
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

4.  HBsAg-induced antigen-specific T and B lymphocyte responses in chronic hepatitis B virus carriers and immune individuals.

Authors:  A Fernan; C J Cayzer; W G Cooksley
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

5.  Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals.

Authors:  S S Chiou; K Yamauchi; T Nakanishi; H Obata
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

6.  In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients.

Authors:  V Barnaba; M Levrero; G Ruberti; A van Dyke; A Perrone; A Musca; F Balsano
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

7.  Anti-idiotypic antibody production in hepatitis B vaccine recipients.

Authors:  K Kobayashi; Y Ueno; H Suzuki; M Miura; R Nagatomi; M Ishii; T Toyota
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

8.  In vitro immune responses to hepatitis B surface antigen (Pre-S2 and S) following remote infection by hepatitis B virus in humans.

Authors:  T R Cupps; J H Hoofnagle; R W Ellis; W J Miller; L Seeff; A Guerrera; J L Gerin; S A Haas-Smith
Journal:  J Clin Immunol       Date:  1989-05       Impact factor: 8.317

9.  Hepatitis B vaccination. Response of alcoholic with and without liver injury.

Authors:  C Mendenhall; G A Roselle; L A Lybecker; L E Marshall; C J Grossman; S A Myre; R E Weesner; D D Morgan
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

10.  Effect of short-term prednisolone therapy in patients with severe chronic type B hepatitis.

Authors:  J Y Yoo; H Y Kim; C K Park; K S Shim; W K Chung
Journal:  Korean J Intern Med       Date:  1989-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.